Bayer/Regeneron’s Eylea (aflibercept) is a fusion protein utilised in the treatment of retinal diseases frequently exacerbated by choroidal neovascularisation, a process in which new blood vessels grow from over-expression of pro-angiogenic proteins such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF).
Roche/Genentech also has a portfolio of anti-VEGF products used to treat ophthalmic indications. Read more here.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
